Chemexpress(SH:688131) Xin Lang Cai Jing·2026-01-12 05:49Core Viewpoint - Haoyuan Pharmaceutical's stock has shown a positive trend with an 11.90% increase year-to-date and a 7.82% increase over the last five trading days, indicating strong market performance and investor interest [1] Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, and listed on June 8, 2021, is located in Shanghai and specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents (68.97%), with product sales contributing 63.42%, raw materials and intermediates 30.46%, technical services 5.55%, and others 0.57% [1] Financial Performance - For the period from January to September 2025, Haoyuan Pharmaceutical achieved a revenue of 2.059 billion yuan, representing a year-on-year growth of 27.18%, and a net profit attributable to shareholders of 237 million yuan, reflecting a 65.09% increase [2] - The company has distributed a total of 160 million yuan in dividends since its A-share listing, with 120 million yuan distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Haoyuan Pharmaceutical was 12,000, a decrease of 6.34% from the previous period, while the average circulating shares per person increased by 6.77% to 17,647 shares [2] - Notable institutional shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 2.3457 million shares, and new entrants such as Huatai-PineBridge Healthcare Mixed Fund and China Europe Medical Innovation Stock A [3]